Most Recent Articles by Virginia Schad, PharmD
Immune-escape mutations and stop-codons may develop in nucleos(t)ide analogue-exposed patients, potentially resulting in hepatitis B virus transmission to vaccinated persons.
Treatment of HCV with sofosbuvir/ledipasvir ± ribavirin after liver or renal transplantation is safe and effective.
Cirrhosis is associated with an increased risk for diabetes mellitus among patients living with HIV.
Liver stiffness progression rates as measured by TE are consistent with traditional fibrosis progression rates in predicting time to cirrhosis.
DAA therapy is highly efficacious for the treatment of HCV infection in individuals >65 years old.
More Articles by Virginia Schad, PharmD
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Clinicians Warn That Zika Virus May Still Be an Area of Concern for Travelers
- Ceftazidime/Avibactam an Effective Option in Serious Gram-Negative Infections
- Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
- Inappropriate Prescribing of Antibiotics High in Urgent Care Centers
- Fixed-Dose Bictegravir Regimen: A Safe Alternative in Adults With HIV-1
- Universal Purchase Programs in the United States May Not Effectively Increase Vaccination Rates
- Tick-Caused Meat Allergy on the Rise in the United States
- Prognostic Biomarkers to Guide Antibiotic Therapy in Critically Ill Patients
- Sofosbuvir/Velpatavir Effective for HCV-Infected Liver Transplant Recipients
- Should Metronidazole Be Recommended for Mild Clostridium difficile Infections?
- Pegylated Interferon, Ribavirin May Improve LV Diastolic Dysfunction in Chronic Hepatitis C
- Automated HIV/Hepatitis C Screening Protocol Demonstrates High Efficacy
- Factors Increasing Risk for Hemorrhagic Stroke After Infective Endocarditis
- Salmonella Outbreak Linked to Hy-Vee Spring Pasta Salad
- Harms Reporting Limited in Trials of Prebiotics, Probiotics, Synbiotics